Zealand Pharma (ZEAL) CMD 2025 summary

Strategic vision and transformation

• Aims to become a generational biotech by redefining obesity management and building a leading metabolic health pipeline, focusing on novel therapies beyond GLP-1s and leveraging over 25 years of peptide and metabolic data with AI/ML-driven innovation.

• Metabolic Frontier 2030 strategy targets five product launches and over ten clinical pipeline programs by 2030, with industry-leading cycle times from idea to clinic.

• Plans to maximize the value of petrelintide, a best-in-class amylin analog, and establish a U.S. commercial presence, supported by a new Boston research hub focused on automation, AI, and novel chemistry.

• Strategic partnerships, notably with Roche, enable 50/50 co-commercialization and infrastructure building in the U.S. and Europe, accelerating the transition to a fully integrated biotech.

• Emphasizes a lean, accountable, patient-driven culture, expanding R&D in Copenhagen and Boston, and aiming to deliver outcomes that increase healthspan.

Pipeline and clinical development

• Petrelintide is positioned as a foundational therapy for durable, high-quality weight loss and maintenance, with Phase II data expected in Q1 2026 and Phase III launch targeted for 2029-2030.

• Survodutide, a GLP-1/glucagon dual agonist, is advancing through large Phase III programs for obesity and MASH, showing up to 18.7% weight loss and pivotal data expected in 2026 with potential launch in 2027.

• Pipeline includes rare disease assets, fixed-dose combinations like petrelintide plus CT388, and multi-hormone approaches to address broader metabolic and comorbidity needs.

• Additional assets include dasiglucagon for congenital hyperinsulinism, glepaglutide for short bowel syndrome, and early-stage Kv1.3 and GIP analogs.

• Plans to deliver 10+ new clinical assets by 2030, leveraging proprietary peptide data and AI/ML for accelerated discovery.

Market dynamics and commercial strategy

• Obesity is a global crisis, projected to affect 50% of adults by 2030, with only 3% of eligible U.S. patients currently treated with GLP-1s and current therapies facing high discontinuation rates.

• Market is shifting from weight loss magnitude to a balanced approach emphasizing patient experience, long-term health gains, and persistence.

• Amylin-based therapies, especially petrelintide, are expected to offer superior tolerability, satiety-driven weight loss, and better patient adherence compared to GLP-1s.

• Two distinct market segments: prescriber-driven (comorbidity focus) and consumer-driven (weight loss and experience focus), with consumer-driven demand and telehealth shaping commercial models.

• MASH remains a major unmet need, with survodutide showing best-in-disease potential in Phase 2 trials.